We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 2

Figure 2. PCr Plots. From: Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease.

Phosphocreatine (PCr) recovery time plots at baseline (A) and year 1 (B) in a patient in the study group treated with simvastatin + ezetimibe with respective PCr recovery time constants of 98 and 121 s.

Amy M. West, et al. J Am Coll Cardiol. ;58(10):1068-1076.
2.
Figure 1

Figure 1. Post-Exercise Calf Muscle Perfusion. From: Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease.

First-pass contrast-enhanced calf muscle perfusion at baseline (A) and year 1 (B) in the same patient in the study group treated with simvastatin + ezetimibe. Increased signal intensity is seen in the anterior tibialis and soleus muscles at both time points (perfusion index: A = 0.37, B = 0.52).

Amy M. West, et al. J Am Coll Cardiol. ;58(10):1068-1076.
3.
Figure 3

Figure 3. Representative MRA Images. From: Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease.

Contrast-enhanced magnetic resonance angiography (MRA) images at baseline (A) and year 1 (B) from a patient in the study group treated with simvastatin + ezetimibe showing improvement in the appearance of superficial femoral artery stenosis (arrows) over time (MRA index: A = 0.44, B = 0.38).

Amy M. West, et al. J Am Coll Cardiol. ;58(10):1068-1076.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk